|
|
Article: Otsuka America Pharmaceutical, Inc. Receives Frost & Sullivan's 2004 Product Innovation of the Year Award for Antipsychotic Medications; Award Recognizes Abilify(R) (aripiprazole) for the Treatment of Patients With Schizophrenia.
- Article from:
- PR Newswire
- Article date:
- September 15, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ROCKVILLE, Md., Sept. 15 /PRNewswire/ -- Otsuka America Pharmaceutical, Inc., (OAPI) is pleased to announce that Abilify(R) (aripiprazole) is the recipient of Frost & Sullivan's 2004 Product Innovation of the Year Award for Antipsychotic Medications. In a recent study on U.S. Antipsychotic Medications Markets, Frost & Sullivan highlighted the success of OAPI in developing and commercializing Abilify(R) (aripiprazole). Because Abilify has a unique pharmacology among atypical antipsychotics and has demonstrated proven efficacy with a comprehensive tolerability and safety profile, it is an important therapy for people in need of treatment options for schizophrenia.
Related newspaper, magazine, and journal articles:
|
|
Article: Otsuka America Pharmaceutical, Inc. Launches ...
PR Newswire;
April 26, 2005 ;
700+ words
... ... PRNewswire/ -- Otsuka America Pharmaceutical, Inc. (OAPI) today ... Executive Officer of Otsuka America Pharmaceutical, Inc. "Participating ... worldwide." About Otsuka America Pharmaceutical, Inc. (OAPI) Otsuka ...
|
|